Wei Zhang

Dr. Wei Zhang

Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
TSTiago C. Silva
Tiago C. Silva
WZWei Zhang
Wei Zhang
JYJuan I. Young
Juan I. Young
LGLissette Gomez
Lissette Gomez
MSMichael A. Schmidt
Michael A. Schmidt
Lily WangLily Wang
Lily Wang
Background: Sex is increasingly recognized as a significant factor contributing to the biological and clinical heterogeneity in AD. There is also growing evidence for the prominent role of DNA methylation (DNAm) in Alzheimer’s disease (AD). Methods: We studied sex-specific DNA methylation differences in the blood samples of AD subjects compared to cognitively normal subjects, by performing sex-specific meta-analyses of two large blood-based epigenome-wide association studies (ADNI and AIBL), which included DNA methylation data for a total of 1284 whole blood samples (632 females and 652 males). Within each dataset, we used two complementary analytical strategies, a sex-stratified analysis that examined methylation to AD associations in male and female samples separately, and a methylation-by-sex interaction analysis that compared the magnitude of these associations between different sexes. After adjusting for age, estimated immune cell type proportions, batch effects, and correcting for inflation, the inverse-variance fixed-effects meta-analysis model was used to identify the most consistent DNAm differences across datasets. In addition, we also evaluated the performance of the sex-specific methylation-based risk prediction models for AD diagnosis using an independent external dataset. Results: In the sex-stratified analysis, we identified 2 CpGs, mapped to the PRRC2A and RPS8 genes, significantly associated with AD in females at a 5% false discovery rate, and an additional 25 significant CpGs (21 in females, 4 in males) at P-value < 1×10−5. In methylation-by-sex interaction analysis, we identified 5 significant CpGs at P-value < 10−5. Out-of-sample validations using the AddNeuroMed dataset showed in females, the best logistic prediction model included age, estimated immune cell-type proportions, and methylation risk scores (MRS) computed from 9 of the 23 CpGs identified in AD vs. CN analysis that are also available in AddNeuroMed dataset (AUC = 0.74, 95% CI: 0.65–0.83). In males, the best logistic prediction model included only age and MRS computed from 2 of the 5 CpGs identified in methylation-by-sex interaction analysis that are also available in the AddNeuroMed dataset (AUC = 0.70, 95% CI: 0.56–0.82). Conclusions: Overall, our results show that the DNA methylation differences in AD are largely distinct between males and females. Our best-performing sex-specific methylation-based prediction model in females performed better than that for males and additionally included estimated cell-type proportions. The significant discriminatory classification of AD samples with our methylation-based prediction models demonstrates that sex-specific DNA methylation could be a predictive biomarker for AD. As sex is a strong factor underlying phenotypic variability in AD, the results of our study are particularly relevant for a better understanding of the epigenetic architecture that underlie AD and for promoting precision medicine in AD.

7 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
WZWei Zhang
Wei Zhang
ELEmma Li
Emma Li
LWLily Wang
Lily Wang
BLBrian Lehmann
Brian Lehmann
XCXi Steven Chen
Xi Steven Chen
Triple-negative breast cancer (TNBC) is a heterogeneous disease with varying responses to neoadjuvant chemotherapy (NAC). The identification of biomarkers to predict NAC response and inform personalized treatment strategies is essential. In this study, we conducted large-scale gene expression meta-analyses to identify genes associated with NAC response and survival outcomes. The results showed that immune, cell cycle/mitotic, and RNA splicing-related pathways were significantly associated with favorable clinical outcomes. Furthermore, we integrated and divided the gene association results from NAC response and survival outcomes into four quadrants, which provided more insights into potential NAC response mechanisms and biomarker discovery.

5 January 2025 in Translational Oncology
Verified
Journal Article
Open access
WZWei Zhang
Wei Zhang
CWChao Wu
Chao Wu
HHHanchen Huang
Hanchen Huang
PBPaulina Bleu
Paulina Bleu
WZWini Zambare
Wini Zambare
XCXi Steven Chen
Xi Steven Chen
Colorectal cancer (CRC) presents significant challenges in chemotherapy response prediction due to its molecular heterogeneity. Current methods often fail to account for the complexity and variability inherent in individual tumors. We developed a novel approach using matched CRC tumor and organoid gene expression data. We applied Consensus Weighted Gene Co-expression Network Analysis (WGCNA) across three datasets: CRC tumors, matched organoids, and an independent organoid dataset with IC50 drug response values, to identify key gene modules and hub genes linked to chemotherapy response, particularly 5-fluorouracil (5-FU). Our integrative analysis identified significant gene modules and hub genes associated with CRC chemotherapy response. The predictive model built from these findings demonstrated superior accuracy over traditional methods when tested on independent datasets. The matched tumor-organoid data approach proved effective in capturing relevant biomarkers, enhancing prediction reliability. This study provides a robust framework for improving CRC chemotherapy response predictions by leveraging matched tumor and organoid gene expression data. Our approach addresses the limitations of previous methods, offering a promising strategy for personalized treatment planning in CRC. Future research should aim to validate these findings and explore the integration of more comprehensive drug response data. This research was supported by US National Cancer Institute grant R37CA248289, and Sylvester Comprehensive Cancer Center. which receives funding from the National Cancer Institute award P30CA240139. This work was supported by National Institutes of Health (NIH) under the following grants: T32CA009501-31A1 and R37CA248289. This work was also supported by the MSK P30CA008748 grant.

9 December 2025 in GigaScience
Verified
Journal Article
Open access
WZWei Zhang
Wei Zhang
HHHanchen Huang
Hanchen Huang
LWLily Wang
Lily Wang
BLBrian D Lehmann
Brian D Lehmann
XCXi Steven Chen
Xi Steven Chen
Background: High-throughput technologies now produce a wide array of omics data, from genomic and transcriptomic profiles to epigenomic and proteomic measurements. Integrating multiple omics layers measured on the same samples can reveal cross-layer molecular hubs that single-layer analyses miss. However, many existing integrative methods rely on linear assumptions or univariate feature importance, limiting their ability to capture nonlinear and interaction-driven dependencies across data modalities. Results: We present an unsupervised, multivariate random forest (MRF) framework with an inverse minimal depth (IMD) importance to prioritize shared biomarkers across omics. In each forest, one layer serves as a multivariate response and the other as predictors; IMD summarizes how early a predictor (or response maximal splitting response variable) appears across trees, yielding interpretable, cross-layer feature rankings. We provide two IMD-based selection strategies and introduce an optional IMD power transform to enhance sensitivity to interaction signals. In extensive simulations spanning linear, nonlinear, and interaction regimes, our method matches sparse partial least squares/canonical correlation analysis under linear settings and outperforms them as nonlinearity increases, while adapted univariate ensemble learners (random forest, gradient boosting machine, XGBoost) underperform in the multivariate, unsupervised context. Applied to breast invasive carcinoma and colon adenocarcinoma in The Cancer Genome Atlas (TCGA), MRF-IMD identifies genes, CpGs, and microRNAs enriched for cancer-relevant pathways and yields more robust survival stratification than linear integrators with matched model sizes. In a TCGA pan-cancer analysis, MRF-IMD features achieve a higher Adjusted Rand Index than alternatives and recover coherent tumor-type clusters; in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the integrative signature improves dementia progression stratification over a published methylation risk score. Conclusions: MRF-IMD provides a scalable and interpretable framework for multiomics integration that reliably identifies cross-layer biomarkers when nonlinear and interaction-driven dependencies are present. This approach advances robust biomarker discovery beyond the limits of linear integrative methods.

6 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
WZWei Zhang
Wei Zhang
HHHanchen Huang
Hanchen Huang
LWLily Wang
Lily Wang
BLBrian D. Lehmann
Brian D. Lehmann
XCXi Steven Chen
Xi Steven Chen
High-throughput technologies now produce a wide array of omics data, from genomic and transcriptomic profiles to epigenomic and proteomic measurements. Integrating these diverse data types can yield deeper insights into the biological mechanisms driving complex traits and diseases. Yet, extracting key shared biomarkers from multiple data layers remains a major challenge. We present a multivariate random forest (MRF)–based framework enhanced by a novel inverse minimal depth (IMD) metric for integrative variable selection. By assigning response variables to tree nodes and employing IMD to rank predictors, our approach efficiently identifies essential features across different omics types, even when confronted with high-dimensionality and noise. Through extensive simulations and analyses of multi-omics datasets from The Cancer Genome Atlas, we demonstrate that our method outperforms established integrative techniques in uncovering biologically meaningful biomarkers and pathways. Our findings show that selected biomarkers not only correlate with known regulatory and signaling networks but can also stratify patient subgroups with distinct clinical outcomes. The method’s scalable, interpretable, and user-friendly implementation ensures broad applicability to a range of research questions. This MRF-based framework advances robust biomarker discovery and integrative multi-omics analyses, accelerating the translation of complex molecular data into tangible biological and clinical insights.